Department of Psychiatry, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198-5581, USA.
Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):941-55. doi: 10.1016/j.chc.2012.07.005.
This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.
本文介绍了现有注意缺陷多动障碍 (ADHD) 药物治疗的实际应用、其制剂和作用持续时间，以及食品和药物管理局的批准程度。它提供了关于这些药物的短期和长期安全性的数据，它们在伴有共病的 ADHD 中的应用，以及制定个体化、有效和耐受良好的药物治疗计划的策略。本文介绍了一个以患有 ADHD 的男性儿童为重点的临床案例。还介绍了 ADHD 药物治疗和食品和药物管理局批准情况、托莫西汀和兴奋剂对照试验、不良反应和 ADHD 药物治疗，以及给药系统和作用持续时间。
